Clinical Trial of Safety (Reactogenicity) and Immunogenicity of Needle-Free Jet Injection of Reduced-Dose, Intradermal Influenza Vaccine [Vaxigrip; sanofi pasteur] Administered to greater than or equal to 6 to less than 24 Month-Old Infants and Toddlers in the Dominican Republic.

Trial Profile

Clinical Trial of Safety (Reactogenicity) and Immunogenicity of Needle-Free Jet Injection of Reduced-Dose, Intradermal Influenza Vaccine [Vaxigrip; sanofi pasteur] Administered to greater than or equal to 6 to less than 24 Month-Old Infants and Toddlers in the Dominican Republic.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 08 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 27 Oct 2009 Planned end date changed from 1 Dec 2009 to 1 May 2010 as reported by ClinicalTrials.gov.
    • 27 Oct 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top